



TO THE SECURITIES MARKET NATIONAL COMMISSION

Madrid, 7 February 2025

In compliance with the reporting requirements provided for in article 226 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “**ROVI**” or the “**Company**”) hereby informs the National Securities Market Commission as follows:

INSIDE INFORMATION

In the context of the preliminary closing of the year 2024, in relation to the ROVI’s EBITDA levels¹ at the end of said year, the Company wishes to inform you in advance that it forecasts that said EBITDA levels will be lower, within a range of between 10% and 15%, than the 2024 EBITDA levels according to the market consensus.

This revision of the market consensus in relation to the EBITDA is due basically to lower expected activity in the contract manufacturing business (CDMO) during the fourth quarter of 2024.

The full results for 2024 will be published on 25 February 2025. At that time, the Company will provide information on the situation and an analysis of its guidance for 2025.

At any event, ROVI maintains its guidance for the current year 2025 as announced previously.

Mr Juan López-Belmonte Encina
Chairman of the Board of Directors and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.

¹ The **EBITDA** (“Earnings Before Interest, Tax, Depreciation and Amortization”) is an indicator that measures the operating profit before deduction of interest, taxes, depreciation and amortisation. It is used by Management to analyse the results over time and is an indicator that is commonly used in assessing companies. The EBITDA is calculated as the profit before: taxes, interest, depreciation and amortisation.